BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

NCT02788513 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

611

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: BI 425809 dose 1
DRUG: BI 425809 dose 2
DRUG: BI 425809 dose 3
DRUG: BI 425809 dose 4
DRUG: Placebo

Sponsor

Boehringer Ingelheim